Development of biomarker of Breast cancer and retrospective analysis to confirm clinical efficacy of the biomarker

• Project/Area Number: 24701000
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor diagnosis
• Research Institution: Tohoku University
• Principal Investigator: TAKAHASHI Shin 東北大学, 加齢医学研究所, 助教 (20431570)
• Project Period (FY): 2012-04-01 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000); Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: バイオマーカー / TP53 / 遺伝子発現プロファイル / 乳がん

Research Abstract

TP53 is tumor suppressor gene and is known as independent prognostic factor in breast cancer. The aim of this study is to develop the biomarker to distinguish TP53 status and to confirm the efficacy of the biomarker. Eighty eight operated breast cancer samples were used. We developed the method to predict TP53 status using gene expression profile. Then we presented that the biomarker could predict the efficacy of chemotherapy by 508 breast cancer cohort data in public database. We expect that the biomarker will improve the prognosis of breast cancer.

Research Products

• [Presentation] TP53 signature predicts the efficacy of neoadjuvant chemotherapy (NAC) of breast cancer (2014)
  • Author(s): Shin Takahashi, Takafumi Fukui, Nobuhisa Gondo, Takanori Ishida, Noriaki Ohuchi, Tadashi Nomizu, Youichiro Kakugawa, Chikashi Ishioka
  • Organizer: 第12回日本臨床学会学術集会
  • Place of Presentation: 福岡(発表確定)
• [Presentation] TP53-mutation status by gene expression signature (TP53 signature) predicts efficacy of neoadjuvant chemotherapy (NAC) and recurrence after surgery in breast cancer (2014)
  • Author(s): Shin Takahashi, Takafumi Fukui, Nobuhisa Gondo, Takanori Ishida, Noriaki Ohuchi, Tadashi Nomizu, Youichiro Kakugawa, Chikashi Ishioka
  • Organizer: American Society of Clinical Oncology 50^<th> annual meeting
  • Place of Presentation: Chicago, USA
• [Presentation] TP53ステータスを利用した乳がんの予後予測バイオマーカーの開発 (2014)
  • Author(s): 高橋信, 福井崇史, 権藤延久, 石岡千加史
  • Organizer: 第111回日本内科学会総会・講演会
  • Place of Presentation: 東京
• [Presentation] TP53 signature predicts the efficacy of neoadjuvant chemotherapy (NAC) of breast cancers. (2014)
  • Author(s): Shin Takahashi
  • Organizer: 第12回日本臨床腫瘍学会学術集会
  • Place of Presentation: 福岡
• [Presentation] TP53-mutation status by gene-expression signature (TP53 signature) and prediction of efficacy of neoadjuvant chemotherapy (NAC) and recurrence after surgery in breast cancer. (2014)
  • Author(s): Shin Takahashi
  • Organizer: American Society of Clinical Oncology 50th annual meeting
  • Place of Presentation: アメリカ・シカゴ
• [Presentation] 遺伝子発現プロファイルによるTP53ステータスの臨床的有用性 (2013)
  • Author(s): 高橋信, 福井崇史, 権藤延久, 石田孝宣, 大内憲明, 野水整, 角川陽一郎, 石岡千加史
  • Organizer: 第51回日本癌治療学会
  • Place of Presentation: 京都
• [Presentation] 遺伝子発現プロファイルによるTP53ステータスの臨床的有用性 (2013)
  • Author(s): 高橋 信
  • Organizer: 第51回日本癌治療学会学術集会
  • Place of Presentation: 京都